Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06681623 · ClinicalTrials.gov registry record
A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)
A clinical trial of Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis, sponsored by Neurology Center of New England P.C..
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT06681623 is a study of Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis that is actively recruiting participants, run by Neurology Center of New England P.C.. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06681623, a study of Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis, is actively recruiting participants, sponsored by Neurology Center of New England P.C..
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
Conditions Studied
Interventions
- DRUG Ublituximab
Study Locations (1)
Massachusetts
- Neurology Center of New England P.C. - Foxborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2027-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06681623
The ClinicalTrials.gov registry entry for NCT06681623 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurology Center of New England P.C., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Ublituximab is the first listed.
NCT06681623 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06681623 about?
NCT06681623 is a clinical study titled "A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)". The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate
What is the current status of trial NCT06681623?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2024-08-13. Estimated completion is 2027-09-30.
What conditions does trial NCT06681623 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis.
What interventions are being tested in trial NCT06681623?
The interventions under investigation include: Ublituximab (DRUG).
Who is sponsoring clinical trial NCT06681623?
This trial is sponsored by Neurology Center of New England P.C., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06681623 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.